Korean biopharmaceutical companies arrived in force at the BIO International Convention in San Diego, hunting licensing deals and CDMO contracts. Samsung Biologics — participating for a fourteenth consecutive year — anchored the national presence with a 140-square-meter booth showcasing end-to-end CDMO services.
Celltrion returned for a seventeenth year to promote its biosimilar lineup and AI-driven research capability, while Lotte Biologics unveiled its first Songdo plant, slated to complete construction in August.
The collective pitch positions Korea as the manufacturing-and-partnership counterpart to U.S. discovery: capacity, quality systems, and speed — with the licensing boom giving Korean discovery science its own growing seat at the table.